Efficacy and Safety of Vismodegib in Advanced Basal-Cell Carcinoma
2012; Massachusetts Medical Society; Volume: 366; Issue: 23 Linguagem: Inglês
10.1056/nejmoa1113713
ISSN1533-4406
AutoresAleksandar Sekulić, Michael R. Migden, Anthony E. Oro, Luc Dirix, Karl D. Lewis, John D. Hainsworth, James Solomon, Simon Yoo, Sarah T. Arron, Philip Friedlander, Ellen S. Marmur, Charles M. Rudin, Anne Lynn S. Chang, Jennifer A. Low, Howard Mackey, Robert L. Yauch, Richard Graham, Josina C. Reddy, Axel Hauschild,
Tópico(s)Nonmelanoma Skin Cancer Studies
ResumoAlterations in hedgehog signaling are implicated in the pathogenesis of basal-cell carcinoma. Although most basal-cell carcinomas are treated surgically, no effective therapy exists for locally advanced or metastatic basal-cell carcinoma. A phase 1 study of vismodegib (GDC-0449), a first-in-class, small-molecule inhibitor of the hedgehog pathway, showed a 58% response rate among patients with advanced basal-cell carcinoma.
Referência(s)